GW26-e2330 Efficacy and safety of 1-hour infusion of recombinant human atrial natriuretic peptide in patients with acute decompensated heart failure: a phase III, randomized, double-blind, placebo-controlled, multicenter trial

Multicenter Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Human Atrial Natriuretic Peptide

ASSA14-10-01 Haemodynamic effects of short-term infusion of recombinant human atrial natriuretic peptide (rhANP) for acute decompensated heart failure: a randomised, double-blind, placebo-controlled, multicenter study

Heart ◽

10.1136/heartjnl-2014-307109.82 ◽

2014 ◽

Vol 101 (Suppl 1) ◽

pp. A32.1-A32

Author(s):

G Wang ◽

P Wang ◽

J Huang ◽

H Tan ◽

W Liu ◽

...

Keyword(s):

Heart Failure ◽

Multicenter Study ◽

Haemodynamic Effects ◽

Short Term ◽

Double Blind ◽

Double Blind Placebo ◽

Human Atrial Natriuretic Peptide

Efficacy and Safety of 1-Hour Infusion of Recombinant Human Atrial Natriuretic Peptide in Patients With Acute Decompensated Heart Failure

Medicine ◽

10.1097/md.0000000000002947 ◽

2016 ◽

Vol 95 (9) ◽

pp. e2947 ◽

Cited By ~ 7

Author(s):

Guogan Wang ◽

Pengbo Wang ◽

Yishi Li ◽

Wenxian Liu ◽

Shugong Bai ◽

...

Keyword(s):

Heart Failure ◽

Natriuretic Peptide ◽

Efficacy And Safety ◽

Human Atrial Natriuretic Peptide ◽

Atrial Natriuretic

Efficacy and Safety of Tolvaptan in Heart Failure Patients with Volume Overload Despite the Standard Treatment with Conventional Diuretics: A Phase III, Randomized, Double-blind, Placebo-controlled Study (QUEST Study)

Cardiovascular Drugs and Therapy ◽

10.1007/s10557-011-6304-x ◽

2011 ◽

Vol 25 (S1) ◽

pp. 33-45 ◽

Cited By ~ 91

Author(s):

Masunori Matsuzaki ◽

◽

Masatsugu Hori ◽

Tohru Izumi ◽

Masatake Fukunami

Keyword(s):

Heart Failure ◽

Standard Treatment ◽

Volume Overload ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Heart Failure Patients

Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA‐RESPONSE‐AHF)

European Journal of Heart Failure ◽

10.1002/ejhf.1713 ◽

2020 ◽

Vol 22 (4) ◽

pp. 713-722 ◽

Cited By ~ 32

Author(s):

Kevin Damman ◽

Joost C. Beusekamp ◽

Eva M. Boorsma ◽

Henk P. Swart ◽

Tom D.J. Smilde ◽

...

Keyword(s):

Heart Failure ◽

Pilot Study ◽

Clinical Outcomes ◽

Double Blind ◽

Double Blind Placebo

GW25-e3203 Hemodynamic effects of short-term infusion of recombinant human atrial natriuretic peptide (rhANP) for congestive heart failure: a randomized, double-blind, placebo-controlled study

Journal of the American College of Cardiology ◽

10.1016/j.jacc.2014.06.844 ◽

2014 ◽

Vol 64 (16) ◽

pp. C182-C183

Author(s):

Wang Pengbo ◽

Huang Jie ◽

Tan Huiqiong ◽

Liu Wenxian ◽

Zhang Jian ◽

...

Keyword(s):

Heart Failure ◽

Congestive Heart Failure ◽

Natriuretic Peptide ◽

Controlled Study ◽

Hemodynamic Effects ◽

Short Term ◽

Double Blind ◽

Double Blind Placebo ◽

Human Atrial Natriuretic Peptide

Effect of the Adenosine A1 Receptor Antagonist, KW-3902, on Diuresis and Renal Function in Patients with Acute Decompensated Heart Failure Refractory to Maximum Doses of Conventional Diuretics: A Randomized, Double-Blind, Placebo Controlled, Dose Escalation Study

Journal of Cardiac Failure ◽

10.1016/j.cardfail.2006.06.281 ◽

2006 ◽

Vol 12 (6) ◽

pp. S82-S83 ◽

Cited By ~ 2

Author(s):

Michael M. Givertz ◽

Michael Tansey ◽

Leeanne L. Pearson ◽

Tara K. Fields ◽

Howard C. Dittrich

Keyword(s):

Heart Failure ◽

Renal Function ◽

Dose Escalation ◽

Dose Escalation Study ◽

Double Blind ◽

Double Blind Placebo ◽

Adenosine A1 ◽

A1 Receptor

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

Case Medical Research ◽

10.31525/ct1-nct04033354 ◽

2019 ◽

Author(s):

Keyword(s):

Stage Iiib ◽

Phase Iii ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

First Line Treatment

A Randomized, Double-blind, Placebo‑Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Case Medical Research ◽

10.31525/ct1-nct04063163 ◽

2019 ◽

Author(s):

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

Extensive Stage

Faculty Opinions recommendation of Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1146988.604098 ◽

2009 ◽

Author(s):

Frank Pessler

Keyword(s):

Juvenile Idiopathic Arthritis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Withdrawal Phase ◽

Systemic Onset

Faculty of 1000 evaluation for Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718030851.793482493 ◽

2013 ◽

Author(s):

Joanne Jordan ◽

Amanda Nelson

Keyword(s):

Clinical Trial ◽

Sustained Release ◽

Hip Osteoarthritis ◽

Randomised Clinical Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Multicentre Phase ◽

Parallel Group